Navigation Links
Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
Date:4/23/2008

More than 90% of CIA patients treated with PBI-1402 did not require blood

transfusion.

MONTREAL, April 23 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces that oral PBI-1402 demonstrates significant activity in patients with chemotherapy-induced anemia ("CIA"), and reduces the need for red blood cell ("RBC") transfusion.

Only 2 patients out of 28 (7%) treated with PBI-1402 required a RBC transfusion, a response rate greater than 90% with regards to this clinical objective. In the March 13, 2008 FDA briefing document, the Oncologic Drugs Advisory Committee emphasizes that the primary objective of treating CIA patients with erythropoiesis-stimulating agents ("ESAs") as being the ability to reduce the need for RBC transfusion. The Advisory Committee cites that approximately 50% of anemic patients receiving chemotherapy required RBC transfusion, and 20%-25% of patients treated with ESAs still required RBC transfusions.

"These results are very exciting and meet the primary objective that formed the basis for FDA approval of other ESAs in CIA patients," states Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "This new encouraging data further supports the potential role PBI-1402 could play in the management of anemia in patients with cancer," added Mr. Laurin.

CIA patients enrolled in the study received a once daily oral dose of PBI-1402 during a period of eight weeks while undergoing their normal course of chemotherapy. All patients enrolled have completed the PBI-1402 treatment period.

About PBI-1402

PBI-1402 is an orally active compound being developed to treat different types of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and does not act through EPO receptor. ProMetic has recently expanded its clinical program for PBI-1402 into the treatment of anemia in patients with myelodysplastic syndrome
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
2. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
3. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
4. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
5. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
6. Job-related stress: NIST demonstrates fatigue effects in silicon
7. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
8. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
9. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
10. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
11. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...6 EUCODIS Bioscience, a company,de...g enzymes for the,chemical industry announced toda...th Bio Sidus, the leading biopharmaceutical compan... EUCODIS Bioscience exclusive access - for the sea...tary collection of,psychrophilic bacteria strains ...
(Date:11/6/2009)...rstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDA...unced updated results from a Phase II study of int...astatic to the lung in a poster presentation at th...eeting held in Miami Beach, Florida, from November...Phase II Study of Intravenous REOLYSIN (Wild-type ...
(Date:11/5/2009)... . . , Fuel economy ratings for the new 2010 m...ueleconomy.gov web site, which Oak Ridge National...epartment of Energy and the U.S. Environmental Pro... best fuel economy list are hybrid electrics, led ...is list proves that hybrids have gone mainstream,"...
(Date:11/5/2009)...wswire/ -- DSM Pharmaceutical Products today annou...h Galenix, Saint Jean D,Illac, France, where DSM w...g partner for Galenix commercial products on a glo...on business development opportunities co-marketing...strength of Galenix in drug product development an...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...raged by the numerous positive signs that biotech ...just a few: , ,& bull; The coming of the Olympics ...e continued acquisition of Midwest biotech compan...gnize the value of Midwest products and technology...icly traded companies. , ,Bone Care International ...
...isconsin-Madison faculty have created a new dual-d...policy to train students how to apply such knowled...he neurobiology of violence and aggression," says ...y policy and one of two co-organizers of the new p...esponsible for intelligence and creativity? How wi...
... agricultural equipment manufacturer Gehl Co. ha... handler operator to control boom functions using ...tside the cab, or from within a personnel work pla... lower, extend and retract the boom, and start and...imension of functionality to the machine without o...
Other Biology Technology:Midwest biotech on a roll 2Midwest biotech on a roll 3Midwest biotech on a roll 4UW offers new program in neuroscience and public policy 2
(Date:11/4/2009)... BEDFORD, Mass., Oct. 20 ...of broadband technology and biometrics software, t...rter ended September 30, 2009. ,, Michael Tza..., said, "Earlier today, we announced an agreement ...to Lantiq, a new fabless semiconductor company bei...
(Date:11/4/2009)... NEW YORK, Oct. 27 Global Rainmake... and advanced R&D laboratory, today announced ... is prepared to actively commercialize its suite o...iometric security offerings. ,, During the past...s of dollars to develop and deploy a series of cor...
(Date:11/3/2009)...DISON, WI, NOVEMBER 4, 2009 -- The world,s greate...ng grape variety, human input, and something calle...eyard site, soil, and climate. , Experts will ...n a symposium on Wednesday, Nov. 4 in Pittsburgh. ... presented in two parts at the 2009 Annual Meeting...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Great wines come from great soils 2Oncothyreon to present at Rodman Renshaw Global Healthcare Conference 13822 1Service Dogs Help Traumatized Veterans Heal 56119 1Service Dogs Help Traumatized Veterans Heal 56119 2Service Dogs Help Traumatized Veterans Heal 56119 3Council for American Medical Innovation to Host Capitol Hill Breakfast Briefing on Education and Immigration 3A The Building Blocks of Innovation 56116 1Council for American Medical Innovation to Host Capitol Hill Breakfast Briefing on Education and Immigration 3A The Building Blocks of Innovation 56116 2
... birth are staggering. In Canada, outlays for spec...mated to be almost $2 billion per year. In a 5-yea...researchers found that giving nitroglycerin to mot...icant improvement in their baby’s health. The resu... of the American Journal of Obstetrics & Gynec...
...that normally suppress tumor growth. Now, for the ...ivating one of those genes in mice can cause tumor...ence that the tumor suppressor gene p53 is a promi...n find drugs that restore p53 function in human tu... effective cancer treatments," said David Kirsch o...
... University School of Medicine in St. Louis, livin...thout needing any coaxing. Then, because of the un... scanning after being injected into mice. , Devel...D., and Gregory Lanza, M.D., Ph.D., the nanopartic... directly track cells used in medical treatments u...
Other Biology News:Reactivated gene shrinks tumors 2Reactivated gene shrinks tumors 3Nanoparticles can track cells deep within living organisms 2Nanoparticles can track cells deep within living organisms 3
ELISA Strips from Santa Cruz Biotechnology, Inc.
...ides offers multiple drive technologies including ...d manual. With this series, users can construct hi... These slides also offer anti-cage creep cross-rol...eters, integrated home/ limit switches, and high-f...
EGTA, Molecular Biology Grade from Research Organics, Inc.
EGTA, Molecular Biology Grade from Research Organics, Inc.
Biology Products: